<DOC>
	<DOCNO>NCT00602082</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , streptozocin , cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give capecitabine together streptozocin effective without cisplatin treat neuroendocrine tumor . PURPOSE : This randomized phase II trial study give capecitabine together streptozocin see well work compare without cisplatin treat patient unresectable metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>Capecitabine Streptozocin With Without Cisplatin Treating Patients With Unresectable Metastatic Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine objective response rate patient neuroendocrine tumor treat capecitabine streptozocin without cisplatin . Secondary - To determine overall response rate , include objective biochemical response , regimen . - To determine functional response regimen . - To determine toxicity regimen . - To identify optimal drug dos regimen recommend subsequent phase III trial . - To determine progression-free overall survival patient receive regimen . - To determine quality life patient . - To determine molecular marker predictive response chemotherapy . OUTLINE : This multicenter study . Patients stratify accord site origin ( know vs unknown primary site ) , prior antitumor treatment , tumor function ( functional v nonfunctional ) , study center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive streptozocin IV 2 hour day 1 oral capecitabine twice daily day 1-21 . - Arm II : Patients receive cisplatin IV 2 hour day 1 streptozocin capecitabine arm I . In treatment arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients complete EORTC QLQC30 questionnaire EORTC QLQ-GI.NET21 module quality-of-life assessment baseline , every 9 week treatment , 12 week post-treatment . Tumor tissue obtain baseline assess Ki67 mitotic index . Novel tissue-specific transcription factor ( e.g. , CDX2 ) also assess . Blood sample collect baseline 9 week examine DNA , RNA , proteomic analysis . After completion study therapy , patient follow every 12 week .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Streptozocin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable , advanced , and/or metastatic disease meet one follow type : Gastroenteroneuroendocrine tumor foregut Pancreatic neuroendocrine tumor Neuroendocrine tumor unknown primary Measurable disease , define least 1 lesion accurately measure least 1 dimension ( long diameter ) ≥ 20 mm conventional CT scan ≥ 10 mm spiral CT scan MRI No bronchial neuroendocrine tumor ( NETs ) NETs primary site situate organ diaphragm ( e.g. , laryngeal pharyngeal NETs ) PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Hemoglobin ≥ 10 g/dL Platelet count ≥ 100,000/mm³ WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Bilirubin ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN AST ALT ≤ 5 time ULN GFR ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No serious uncontrolled illness would preclude study participation No medical psychiatric condition would influence ability provide consent PRIOR CONCURRENT THERAPY : At least 3 week since prior interferon therapy No prior systemic chemotherapy chemotherapy administer part chemoembolization regimen , condition No receptortargeted radiolabeled therapy within past 6 month No investigational agent within past 4 week Prior concurrent somatostatin analogue allow provide symptom longer control treatment document measurable disease progression serial CT scan perform 6 month apart No palliative radiotherapy involve lesion use measure disease Palliative radiotherapy region involve measurement disease allow No concurrent chemotherapy condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>pancreatic alpha cell adenoma</keyword>
	<keyword>pancreatic alpha cell carcinoma</keyword>
	<keyword>pancreatic beta islet cell adenoma</keyword>
	<keyword>pancreatic beta islet cell carcinoma</keyword>
	<keyword>pancreatic delta cell adenoma</keyword>
	<keyword>pancreatic delta cell carcinoma</keyword>
	<keyword>pancreatic G-cell adenoma</keyword>
	<keyword>pancreatic G-cell carcinoma</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>islet cell carcinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
</DOC>